Ipsen Enters into an Option Agreement with Skyhawk Therapeutics for Two RNA Targeting Small Molecules in Rare Neurological Diseases
Shots:
- Ipsen and Skyhawk Therapeutics signed worldwide collaboration to discover and develop RNA targeting small molecules for rare neurological diseases
- Under the collaboration, Ipsen has option to acquire exclusive global rights to develop and commercialize two molecules, post successful development candidate validation
- As per the terms of agreement, Skyhawk will receive ~$1.8B in upfront, development, regulatory & commercial milestones, plus tiered royalties
Ref: Ipsen | Image: Ipsen
Related News:- Ipsen and Sutro Biopharma Collaborate to Develop and Commercialize STRO-003 for Treating Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
